Malberti F, Surian M, Farina M, Vitelli E, Mandolfo S, Guri L, De Petri G C, Castellani A
Department of Nephrology, Ospedale Maggiore, Lodi, Italy.
Blood Purif. 1991;9(5-6):285-95. doi: 10.1159/000170026.
This study was undertaken to compare the effect of 1 year hemodialysis (HD) or hemodiafiltration (HDF) treatment on peripheral neuropathy. Thus 21 of 42 patients on chronic HD (1-1.3 m2 cuprophane dialyzer, Qb 300 ml/min) were switched to HDF (1.3 m2 polysulfone dialyzer, Qb 400 ml/min, substitution volume 9-13 liters, ultrafiltration rate 60-70 ml/min), while the remaining patients were considered as a control group. Treatment time was scheduled both in HD and HDF to maintain adequate BUN levels in relation to protein catabolic rate. However, HDF provided a significantly greater weekly inulin (MW 5,000) clearance than HD (5.8 +/- 1.2 vs. 1.6 +/- 0.2 ml/min; p less than 0.001). HD and HDF groups were comparable for age, time on dialysis and starting electroneurographic parameters, which were on average within the normal range. After 1 year follow-up, creatinine, hematocrit, calcium, phosphate, PTH, BUN, protein catabolic rate and residual GFR were comparable in the two groups, whereas beta 2-microglobulin was significantly reduced in HDF patients (29 +/- 6.7 vs. 38.8 +/- 13.9 mg/l in HD patients, p less than 0.01). During the 1-year treatment, electroneurographic parameters did not change in HDF patients, whereas a significant decrease of ulnar motor nerve conduction velocity, ulnar muscle action potential amplitudes, median sensory nerve conduction velocity and peroneal muscle action potential amplitudes was detected in HD patients. We conclude that HDF might prevent the worsening of the electroneurographic indices occurring during chronic HD treatment, as it provides a more effective removal of middle and larger molecules than HD. The use of a more biocompatible membrane in HDF might further contribute to this favorable effect on uremic neuropathy.
本研究旨在比较1年血液透析(HD)或血液透析滤过(HDF)治疗对外周神经病变的影响。因此,42例接受慢性HD治疗的患者(使用1 - 1.3 m²铜仿膜透析器,血流量300 ml/min)中有21例转为HDF治疗(使用1.3 m²聚砜膜透析器,血流量400 ml/min,置换量9 - 13升,超滤率60 - 70 ml/min),其余患者作为对照组。HD和HDF的治疗时间均根据蛋白质分解代谢率来安排,以维持适当的尿素氮水平。然而,HDF的菊粉(分子量5000)每周清除率显著高于HD(5.8±1.2对1.6±0.2 ml/min;p<0.001)。HD组和HDF组在年龄、透析时间和起始神经电生理参数方面具有可比性,这些参数平均在正常范围内。经过1年随访,两组的肌酐、血细胞比容、钙、磷、甲状旁腺激素、尿素氮、蛋白质分解代谢率和残余肾小球滤过率相当,而HDF患者的β2 - 微球蛋白显著降低(HD患者为38.8±13.9 mg/l,HDF患者为29±6.7 mg/l,p<0.01)。在1年治疗期间,HDF患者的神经电生理参数未发生变化,而HD患者检测到尺神经运动神经传导速度、尺神经肌肉动作电位幅度、正中神经感觉神经传导速度和腓总神经肌肉动作电位幅度显著下降。我们得出结论,HDF可能预防慢性HD治疗期间发生的神经电生理指标恶化,因为它比HD能更有效地清除中大分子。在HDF中使用生物相容性更好的膜可能进一步有助于对尿毒症神经病变产生这种有利影响。